Researchers reported mixed findings for Sanofi Pasteur’s shot in two new papers that were funded by the company.
A health care worker prepares an influenza vaccine in Las Rozas, Spain, in an Oct. 14, 2020, file image. Pablo Blazquez Dominguez/Getty Images
|Updated:
The high-dose influenza vaccine may reduce hospitalizations among older people when compared with the protection from standard flu vaccines, according to new studies that provided mixed results.
Researchers in Spain found signs that the high-dose vaccine made by Sanofi Pasteur reduced hospitalizations compared to a standard shot, but statistical significance was not reached.
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
